Aardvark Therapeutics - ARD-301 - Ownership and Business Overview

Life ScienceCompany

Aardvark Therapeutics - ARD-301 Ownership

Who owns Aardvark Therapeutics - ARD-301?

Aardvark Therapeutics - ARD-301 is owned by SCILEX Pharmaceuticals and Sorrento Therapeutics. It was acquired on March 1, 2021.

Aardvark Therapeutics - ARD-301 Business Overview

Where is Aardvark Therapeutics - ARD-301 headquartered?

Aardvark Therapeutics - ARD-301 is headquartered in San Diego, California.

What sector is Aardvark Therapeutics - ARD-301 in?

Aardvark Therapeutics - ARD-301 is a life science company.

Life Science M&A Summary in 2021

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2021. The largest life science acquisition in 2021 was Pharmaceutical Product Development - which was acquired by Thermo Fisher Scientific for $17.4B.

Join Mergr to view all 397 acquisitions of life science companies in 2021, including 46 acquisitions by private equity firms, and 351 by strategics.

Aardvark Therapeutics - ARD-301

San Diego, California 92130
United States,

Aardvark Therapeutics' ARD-301 proprietary formulation Delayed Burst Release Low Dose Naltrexone (DBR-LDN) used for the treatment of chronic pain, fibromyalgia, and chronic post-COVID syndrome. Aardvark Therapeutics' ARD-301 is based in San Diego, California.


 Subscribe to unlock this and 208,718
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 201K M&A Transactions
  • 204K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.